{"resourceType":"Bundle","id":"3bbdbf93-a745-ee11-be6f-000d3aaa0218","meta":{"versionId":"1","lastUpdated":"2024-05-21T18:26:53.572+00:00"},"identifier":{"system":"http://ema.europa.eu/fhir/epiDocument","value":"3bbdbf93-a745-ee11-be6f-000d3aaa0218"},"type":"document","timestamp":"2024-05-21T18:26:53.4214221+00:00","entry":[{"fullUrl":"http://ema.europa.eu/fhir","resource":{"resourceType":0,"language":6,"text":{"status":"generated","div":"<div xmlns =\"http://www.w3.org/1999/xhtml\">electronic Product Information (ePI) document</div>"},"contained":[{"id":"d72b3c2f-6446-ee11-be6e-000d3aaa0ed0","resourceType":"Binary","contentType":"image/jpeg","data":"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"},{"id":"3e80e428-6446-ee11-be6e-000d3aaa0ed0","resourceType":"Binary","contentType":"image/jpeg","data":"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"},{"id":"d62b3c2f-6446-ee11-be6e-000d3aaa0ed0","resourceType":"Binary","contentType":"image/jpeg","data":"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"},{"id":"d12b3c2f-6446-ee11-be6e-000d3aaa0ed0","resourceType":"Binary","contentType":"image/jpeg","data":"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"},{"id":"d02b3c2f-6446-ee11-be6e-000d3aaa0ed0","resourceType":"Binary","contentType":"image/jpeg","data":"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"}],"extension":[{"url":"https://ema.europa.eu/fhir/extension/documentType","valueReference":{"reference":"Summary of Product Characteristics"}},{"url":"http://ema.europa.eu/fhir/extension/imageReference","valueReference":{"reference":"#d72b3c2f-6446-ee11-be6e-000d3aaa0ed0"}},{"url":"http://ema.europa.eu/fhir/extension/imageReference","valueReference":{"reference":"#3e80e428-6446-ee11-be6e-000d3aaa0ed0"}},{"url":"http://ema.europa.eu/fhir/extension/imageReference","valueReference":{"reference":"#d62b3c2f-6446-ee11-be6e-000d3aaa0ed0"}},{"url":"http://ema.europa.eu/fhir/extension/imageReference","valueReference":{"reference":"#d12b3c2f-6446-ee11-be6e-000d3aaa0ed0"}},{"url":"http://ema.europa.eu/fhir/extension/imageReference","valueReference":{"reference":"#d02b3c2f-6446-ee11-be6e-000d3aaa0ed0"}}],"status":0,"type":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/100000155531/terms/","code":"100000155532","display":"Summary of Product Characteristics (Dutch)"}]},"date":"2024-05-21","author":[{"identifier":{"system":"http://www.test.com","value":"systemuser"}}],"title":"Zoladex","section":[{"id":"3cbdbf93-a745-ee11-be6f-000d3aaa0218","title":"SAMENVATTING VAN DE PRODUCTKENMERKEN","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">&#160;</div>"},"section":[{"id":"3dbdbf93-a745-ee11-be6f-000d3aaa0218","title":"1. NAAM VAN HET GENEESMIDDEL","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-family: 'times new roman', times;\">Zoladex-3,6, implantatiestaafje 3,6 mg</span></p>\n<p><span style=\"font-family: 'times new roman', times;\">Zoladex-10,8, implantatiestaafje 10,8 mg&#160;</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029792","display":"1. NAAM VAN HET GENEESMIDDEL"}]}},{"id":"3ebdbf93-a745-ee11-be6f-000d3aaa0218","title":"2. KWALITATIEVE EN KWANTITATIEVE SAMENSTELLING","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-family: 'times new roman', times; font-size: 11pt;\">De voorgevulde injectiespuit (SafeSystem) bevat een steriel implantatiestaafje.&#160;Dit implantatiestaafje bevat gosereline-acetaat, overeenkomend met 3,6 mg gosereline (Zoladex-3,6) of 10,8 mg gosereline (Zoladex-10,8). &#160;</span></p>\n<p><span style=\"font-family: 'times new roman', times; font-size: 11pt;\">Voor de volledige lijst van hulpstoffen, zie rubriek 6.1.&#160;</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029793","display":"2. KWALITATIEVE EN KWANTITATIEVE SAMENSTELLING"}]}},{"id":"40bdbf93-a745-ee11-be6f-000d3aaa0218","title":"3. FARMACEUTISCHE VORM","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Implantatiestaafje in voorgevulde injectiespuit.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029797","display":"3. FARMACEUTISCHE VORM"}]}},{"id":"41bdbf93-a745-ee11-be6f-000d3aaa0218","title":"4. KLINISCHE GEGEVENS","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">&#160;</div>"},"section":[{"id":"42bdbf93-a745-ee11-be6f-000d3aaa0218","title":"4.1 Therapeutische indicaties","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"margin: 0cm; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zoladex<em>‑3,6:</em></span></p>\n<ul style=\"margin-bottom: 0cm; margin-top: 0px;\">\n<li style=\"margin: 0cm 0cm 0cm 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 13.7953px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Behandeling van gemetastaseerd prostaatcarcinoom, waarbij suppressie van de testosteron&#173;productie gewenst is;</span></li>\n<li style=\"margin: 0cm 0cm 0cm 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 13.7953px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Adjuvante hormoontherapie bij bestraling van pati&#235;nten met lokaal uitgebreid prostaatcarcinoom (Stadia T3-T4 volgens TNM-classificatie of stadium C volgens de AUA);</span></li>\n<li style=\"margin: 0cm 0cm 0cm 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 13.7953px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Matige en ernstige endometriose;</span></li>\n<li style=\"margin: 0cm 0cm 0cm 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 13.7953px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Fibromyomen van de uterus, echter uitsluitend als preoperatieve behandeling tot een maximum van 6 maanden;</span></li>\n<li style=\"margin: 0cm 0cm 0cm 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 13.7953px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Slinken van het endometrium, voorafgaand aan verwijdering van het endometrium;</span></li>\n<li style=\"margin: 0cm 0cm 0cm 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 13.7953px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Behandeling van receptorpositief gemetastaseerd mammacarcinoom bij pre- en perimenopauzale vrouwen in combinatie met tamoxifen, bij wie ovari&#235;ctomie niet geschikt wordt geacht.</span></li>\n</ul>\n<p style=\"margin: 0cm; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"break-after: avoid; margin: 0cm; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zoladex<em>‑10,8:</em></span></p>\n<ul style=\"margin-bottom: 0cm; margin-top: 0px;\">\n<li style=\"margin: 0cm 0cm 0cm 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 13.7953px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Behandeling van gemetastaseerd prostaatcarcinoom, waarbij suppressie van de testosteronproductie gewenst is;</span></li>\n<li style=\"margin: 0cm 0cm 0cm 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 13.7953px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Adjuvante hormoontherapie bij bestraling van pati&#235;nten met lokaal uitgebreid prostaatcarcinoom (Stadia T3-T4 volgens TNM-classificatie of stadium C volgens de AUA).</span></li>\n</ul>\n<p>&#160;</p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029799","display":"4.1 Therapeutische indicaties"}]}},{"id":"43bdbf93-a745-ee11-be6f-000d3aaa0218","title":"4.2 Dosering en wijze van toediening","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">&#160;</div>"},"section":[{"id":"44bdbf93-a745-ee11-be6f-000d3aaa0218","title":"Dosering","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Volwassen mannen</span></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">E&#233;n keer per vier weken (Zoladex‑3,6) of &#233;&#233;n keer per drie maanden (Zoladex‑10,8) een subcutane injectie in de onderhuidse buikstreek (zie de aan de enveloppe gehechte gebruiksaanwijzing) (zie rubriek 5.1).</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Volwassen vrouwen</span></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\">&#160;</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">E&#233;n keer per vier weken een subcutane injectie met Zoladex‑3,6 in de onderhuidse buikstreek (zie de aan de enveloppe gehechte gebruiksaanwijzing). </span></p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Zoladex‑10,8 is niet bestemd voor toepassing bij vrouwen.</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Slinken van het endometrium</span></u></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Bij gebruik voor het doen slinken van het endometrium, voorafgaand aan verwijdering van het endometrium, dient Zoladex‑3,6 met een tussenliggende periode van vier weken twee maal te worden toegediend. Chirurgie dient binnen twee weken na de tweede injectie plaats te vinden.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Endometriose</span></u></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Endometriose moet worden behandeld voor een periode van ten hoogste zes maanden, omdat tot heden geen klinische data beschikbaar is over langere behandelperioden. Er dient niet herhaaldelijk met Zoladex‑3,6 te worden behandeld vanwege het risico op een verlaging van de botdichtheid. Wanneer na zes maanden behandeling van endometriose de klachten opnieuw optreden en verdere behandeling met Zoladex‑3,6 wordt overwogen, dan wordt aanbevolen de botdichtheid te meten voordat een nieuwe behandeling wordt gestart. De gevonden waarden dienen binnen acceptabele grenzen te liggen. Alleen bij ernstige gevallen van endometriose of fibromyomen van de uterus zou een nieuwe behandeling kunnen worden overwogen en dan nadat een jaar is verstreken sinds de vorige behandeling.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Pediatrische pati&#235;nten</span></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zoladex is niet </span>ge&#239;ndiceerd<span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\"> voor toepassing bij kinderen.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Ouderen</span></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Er is geen dosisaanpassing nodig voor ouderen.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Gestoorde nierfunctie</span></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Er is geen dosisaanpassing nodig voor pati&#235;nten met een gestoorde nierfunctie.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Gestoorde leverfunctie</span></em></p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Er is geen dosisaanpassing nodig voor pati&#235;nten met een gestoorde leverfunctie.</p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029801","display":"Dosering"}]}},{"id":"b30ab899-a745-ee11-be6f-000d3aaa0218","title":"Wijze van toediening","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Wees voorzichtig bij het inbrengen van Zoladex in de buikwand vanwege de nabijheid van de onderliggende arteria epigastrica inferior en vertakkingen daarvan.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Wees extra voorzichtig bij het toedienen van Zoladex aan pati&#235;nten met een laag BMI en/of pati&#235;nten die antistollingstherapie krijgen (zie rubriek 4.4).</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">De Zoladex-injectiespuit kan niet gebruikt worden voor aspiratie. Als de naald een groot bloedvat raakt, zal er direct bloed zichtbaar zijn in de kamer van de spuit. Wordt er een bloedvat geraakt, trek dan de naald terug en stelp een eventuele bloeding. Let op mogelijke tekenen van abdominale bloeding. Nadat zeker is gesteld dat de pati&#235;nt hemodynamisch stabiel is, kan een nieuw Zoladex-implantatiestaafje op een andere plek worden ge&#239;njecteerd met een nieuwe injectiespuit.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">De naald is niet in te trekken.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">In het zeldzame geval dat het nodig zou zijn om chirurgisch een Zoladex-implantatiestaafje te verwijderen, kan het staafje m.b.v. echografie worden gelokaliseerd.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Alleen gebruiken indien de verpakking (aluminium enveloppe) onbeschadigd is. Na openen van de aluminium enveloppe direct gebruiken.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Voor een correcte toediening van Zoladex, volg de instructies zoals hieronder weergegeven. Deze instructies zijn ook vermeld op de aan de aluminium enveloppe gehechte gebruiksaanwijzing.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<table class=\"MsoNormalTable\" style=\"border-collapse: collapse !msorm;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td style=\"width: 317.25pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<ol style=\"margin-bottom: 0in; margin-top: 0px;\">\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Laat de pati&#235;nt in een comfortabele positie plaatsnemen met het bovenlichaam iets omhoog. Bepaal een injectieplaats op de buik onder de navel. Reinig de injectieplaats.</span></li>\n</ol>\n</td>\n<td style=\"width: 147.15pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 317.25pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<ol style=\"margin-bottom: 0in; margin-top: 0px;\" start=\"2\">\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Neem de injectiespuit uit het geopende foliezakje en houd de injectiespuit schuin tegen het licht om te controleren of het Zoladex-depot zichtbaar is in het venster (figuur 1).</span></li>\n</ol>\n</td>\n<td style=\"width: 147.15pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<p style=\"text-align: right; margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\"><img src=\"#d72b3c2f-6446-ee11-be6e-000d3aaa0ed0\" annotationsrc=\"~/_entity/annotation/d72b3c2f-6446-ee11-be6e-000d3aaa0ed0\"\" width=\"182\" height=\"123\" /></span></p>\n<p style=\"text-align: right; margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Figuur 1</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 317.25pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<ol style=\"margin-bottom: 0in; margin-top: 0px;\" start=\"3\">\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Trek de plastic veiligheidsclip van de injectiespuit en gooi de clip weg (figuur 2). Verwijder de naaldbeschermer. <strong>Het is niet nodig om luchtbellen te verwijderen. Probeer dit niet, want hierdoor kan het implantatiestaafje uit positie raken.</strong></span></li>\n</ol>\n</td>\n<td style=\"width: 147.15pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<p style=\"text-align: right; margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\"><img src=\"#3e80e428-6446-ee11-be6e-000d3aaa0ed0\" annotationsrc=\"~/_entity/annotation/3e80e428-6446-ee11-be6e-000d3aaa0ed0\"\" width=\"182\" height=\"103\" /></span></p>\n<p style=\"text-align: right; margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Figuur 2</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 317.25pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<ol style=\"margin-bottom: 0in; margin-top: 0px;\" start=\"4\">\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Houd de injectiespuit vast bij de beschermhuls. Pak de buikhuid losjes samen in een plooi. Houd de opening van de naald naar boven gericht. Breng de naald subcutaan in onder een hoek van 30 tot 45 graden totdat de beschermhuls de huid van de pati&#235;nt raakt (figuur 3).</span></li>\n</ol>\n</td>\n<td style=\"width: 147.15pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<p style=\"text-align: right; margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\"><img src=\"#d62b3c2f-6446-ee11-be6e-000d3aaa0ed0\" annotationsrc=\"~/_entity/annotation/d62b3c2f-6446-ee11-be6e-000d3aaa0ed0\"\" width=\"182\" height=\"128\" /></span></p>\n<p style=\"text-align: right; margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Figuur 3</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 317.25pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<ol style=\"margin-bottom: 0in; margin-top: 0px;\" start=\"5\">\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Let op: niet injecteren in spierweefsel of door het buikvlies. Foutieve positie en toedieningshoek worden getoond in figuur 4.</span></li>\n</ol>\n</td>\n<td style=\"width: 147.15pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<p style=\"text-align: right; margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\"><img src=\"#d12b3c2f-6446-ee11-be6e-000d3aaa0ed0\" annotationsrc=\"~/_entity/annotation/d12b3c2f-6446-ee11-be6e-000d3aaa0ed0\"\" width=\"182\" height=\"159\" /></span></p>\n<p style=\"text-align: right; margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Figuur 4</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 317.25pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<ol style=\"margin-bottom: 0in; margin-top: 0px;\" start=\"6\">\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Verplaats de vingers naar de vingergreep. Injecteer het Zoladex-depot door de zuiger volledig naar beneden te drukken. Hierbij kan men een &#8220;klik&#8221; horen en zal de beschermhuls over de naald glijden. Indien de zuiger <strong>niet</strong> volledig is ingedrukt zal de beschermhuls <strong>niet</strong> geactiveerd worden.</span></li>\n</ol>\n</td>\n<td style=\"width: 147.15pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 317.25pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<ol style=\"margin-bottom: 0in; margin-top: 0px;\" start=\"7\">\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Trek de naald terug en laat de beschermhuls verder over de naald glijden (figuur 5).<br />Dek de injectieplaats steriel af. Gooi de injectiespuit in een daarvoor bestemde naaldcontainer.</span></li>\n</ol>\n</td>\n<td style=\"width: 147.15pt; padding: 0in 5.4pt 0in 5.4pt 0in 5.4pt 0in 5.4pt !msorm;\" valign=\"top\">\n<p style=\"text-align: right; margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\"><img src=\"#d02b3c2f-6446-ee11-be6e-000d3aaa0ed0\" annotationsrc=\"~/_entity/annotation/d02b3c2f-6446-ee11-be6e-000d3aaa0ed0\"\" width=\"182\" height=\"125\" /></span></p>\n<p style=\"text-align: right; margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Figuur 5</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zie ook rubriek 6.6.</span></p>\n<p>&#160;</p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029803","display":"Wijze van toediening"}]}}],"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029800","display":"4.2 Dosering en wijze van toediening"}]}},{"id":"b50ab899-a745-ee11-be6f-000d3aaa0218","title":"4.3 Contra-indicaties","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Overgevoeligheid voor de werkzame stof of voor een van de in rubriek 6.1 vermelde hulpstoffen.</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zwangerschap en het geven van borstvoeding (zie rubriek 4.6).</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\">&#160;</p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029805","display":"4.3 Contra-indicaties"}]}},{"id":"b60ab899-a745-ee11-be6f-000d3aaa0218","title":"4.4 Bijzondere waarschuwingen en voorzorgen bij gebruik","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Zoladex is niet ge&#239;ndiceerd voor toepassing bij kinderen, aangezien de veiligheid en werkzaamheid niet zijn vastgesteld bij deze pati&#235;ntengroep.</p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Bij pati&#235;nten die behandeld worden met GnRH-agonisten, zoals gosereline, is er een verhoogd risico op depressie, die ernstig kan zijn. Pati&#235;nten moeten hierover ge&#239;nformeerd worden en bij het optreden van symptomen moet een geschikte behandeling worden ingezet. </span><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Pati&#235;nten die depressief zijn of zijn geweest dienen zorgvuldig gecontroleerd te worden en, indien nodig, behandeld (risico op terugkeer of verergering van de depressie).</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Er is bij Zoladex melding gemaakt van letsel op de plaats van injectie, waaronder pijn, hematoom, bloeding en vaatletsel. Volg aangedane pati&#235;nten en let daarbij op tekenen van abdominale bloeding. In zeer zeldzame gevallen heeft een verkeerde toediening geleid tot vaatletsel en hemorragische shock, waarbij bloedtransfusie en chirurgische interventie nodig waren. Zoladex moet extra voorzichtig worden toegediend aan pati&#235;nten met een laag BMI en/of pati&#235;nten die antistollingstherapie krijgen (zie rubriek 4.2).</p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Er zijn geen gegevens over verwijdering of oplossen van het implantaat.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Mannen</span></u></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></u></p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Pati&#235;nten met hormoonongevoelige tumoren of na orchidectomie reageren niet op behandeling met Zoladex. De toepassing van gosereline dient plaats te vinden door een arts die bekend is met de behandeling van carcinomen met hormonale therapie. Tijdens de eerste week van de behandeling kunnen de klachten en symptomen kortdurend verergeren.</p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt;\">Androgeendeprivatietherapie (suppressie van de testosteronproductie bij prostaatcarcinoom) kan het QT-interval verlengen.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt;\">Bij pati&#235;nten met een voorgeschiedenis van of risicofactoren voor QT-verlenging en bij pati&#235;nten die gelijktijdig geneesmiddelen krijgen die het QT-interval kunnen verlengen (zie rubriek 4.5) dient de arts voorafgaand aan het starten met gosereline een afweging te maken van de voordelen en risico&#8217;s, waaronder de kans op Torsade de pointes.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Het gebruik van Zoladex bij mannen met een verhoogd risico op het ontstaan van urinewegobstructie of met compressie in de wervels moet zorgvuldig worden afgewogen en de pati&#235;nten moeten in de eerste maand nauwlettend worden geobserveerd. Er moet overwogen worden om in het begin een antiandrogeen te gebruiken (bijvoorbeeld cyproteronacetaat 300 mg per dag gedurende 3 dagen v&#243;&#243;r en 3 weken n&#225; aanvang van gosereline) bij het opstarten van de behandeling met een LHRH-analogon, omdat er meldingen zijn dat zo de eventuele sequelen van de initi&#235;le stijging van het serumtestosteron voorkomen kunnen worden. Als compressie van de rugwervels of nierinsuffici&#235;ntie aanwezig is of optreedt als gevolg van urinewegobstructie, dient specifieke standaardbehandeling van deze complicaties te worden ingesteld.</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Het gebruik van LHRH-agonisten kan een verlaging van de botmineraaldichtheid veroorzaken. Bij mannen laten gegevens uit voorlopig onderzoek zien dat het gebruik van een bisfosfonaat in combinatie met een LHRH-agonist botmineraalverlies kan beperken.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Bijzondere voorzichtigheid is noodzakelijk bij pati&#235;nten met additionele risicofactoren voor osteoporose (bijvoorbeeld chronisch alcoholmisbruik, roken, lange-termijnbehandeling met anticonvulsiva of corticostero&#239;den, familiaire historie van osteoporose).</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Pati&#235;nten met hypertensie dienen zorgvuldig gecontroleerd te worden.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Een afname van glucosetolerantie is aangetoond bij mannen die met LHRH-agonisten behandeld werden. Dit kan zich uiten als diabetes of verlies van glykemiecontrole bij pati&#235;nten die reeds diabetes mellitus hebben. Daarom dient het te worden overwogen om het glucosegehalte van het bloed te monitoren. </span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">In een farmaco-epidemiologische studie van LHRH-agonisten zijn myocardinfarct en hartfalen waargenomen tijdens de behandeling van prostaatkanker. Het risico lijkt hoger bij gelijktijdig gebruik met anti-androgenen.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Vrouwen (all&#233;&#233;n </span></u><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zoladex</span></u><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">-3,6)</span></u></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Indicatie borstkanker</span></u></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Verminderde botmineraaldichtheid.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Het gebruik van LHRH-agonisten kan een afname van de botmineraaldichtheid veroorzaken. Na twee jaar behandeling voor borstkanker, bedraagt het gemiddelde verlies van botmineraaldichtheid 6,2% en 11,5% bij respectievelijk de femurhals en de lumbale wervelkolom. Het is aangetoond dat dit verlies gedeeltelijk reversibel is met herstel tot 3,4% en 6,4% in vergelijking tot de basiswaarden voor respectievelijk de femurhals en de lumbale wervelkolom bij een follow-up na een jaar. Dit herstel is echter gebaseerd op zeer beperkte gegevens.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Bij de meerderheid van de vrouwen wijzen huidige beschikbare gegevens er op dat herstel van botverlies optreedt na het staken van de behandeling.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Gegevens uit voorlopig onderzoek suggereren dat het gebruik van gosereline in combinatie met tamoxifen bij pati&#235;nten met borstkanker het verlies van botmineraal kan beperken.</span></p>\n<p style=\"break-after: auto; margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Goedaardige indicaties</span></u></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Verlies van botmineraaldichtheid</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Waarschijnlijk veroorzaakt het gebruik van LHRH-agonisten vermindering van de botmineraaldichtheid met gemiddeld 1% per maand gedurende een 6 maanden durende behandelingsperiode. Met elke 10% verlies van botmineraaldichtheid wordt de kans op fracturen met 2-3 keer verhoogd. </span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Bij de meerderheid van de vrouwen, wijzen huidige beschikbare gegevens er op dat herstel van botverlies optreedt na het staken van de behandeling.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Het is aangetoond dat bij pati&#235;nten die gosereline krijgen voor de behandeling van endometriose, de toevoeging van hormonale substitutietherapie het verlies van botmineraaldichtheid en het optreden van vasomotore symptomen worden beperkt. </span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Er zijn geen specifieke gegevens beschikbaar voor pati&#235;nten met vastgestelde osteoporose of met risicofactoren voor osteoporose (bijvoorbeeld chronisch alcoholmisbruik, roken, lange-termijnbehandeling met geneesmiddelen die de botmineraaldichtheid verlagen, zoals anticonvulsiva of corticostero&#239;den, familiaire geschiedenis van osteoporose, ondervoeding, zoals anorexia nervosa). Aangezien verlaging van de botmineraaldichtheid waarschijnlijk nadeliger is bij deze pati&#235;nten, dient behandeling met gosereline op individuele basis te worden overwogen en all&#233;&#233;n te worden ingesteld als na een zeer zorgvuldige beoordeling de voordelen van de behandeling afwegen tegen de risico&#8217;s. Overwogen moet worden om additionele maatregelen te treffen om het verlies van botmineraaldichtheid tegen te gaan.</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><em><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Onttrekkingsbloeding</span></u></em></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">In de beginfase van de behandeling met gosereline treedt bij sommige vrouwen vaginale bloeding op die in duur en intensiteit variabel is. Als vaginale bloeding optreedt, is dit gewoonlijk in de eerste maand na het starten van de behandeling. Dergelijke bloeding is waarschijnlijk te wijten aan verlaging van de oestrogeenspiegel. Naar verwachting stopt deze spontaan. Als bloeding aanhoudt, moet de oorzaak hiervan opgespoord worden.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Er zijn geen klinische gegevens over het effect van de behandeling van benigne gynaecologische aandoeningen met gosereline 3,6&#160;mg gedurende perioden langer dan 6 maanden.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"line-height: normal; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Het gebruik van gosereline kan de cervicale weerstand verhogen en men dient voorzichtig te zijn bij het dilateren van de cervix.</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Net als met andere LHRH-agonisten, zijn meldingen van het ovariumhyperstimuleringssyndroom (OHSS) geassocieerd met het gebruik van gosereline 3,6 mg implantaat, in combinatie met gonadotrofine. De stimuleringscyclus dient zorgvuldig gecontroleerd te worden om pati&#235;nten met een kans op het ontstaan van OHSS te identificeren. Als een risico op OHSS aanwezig is, dient humaan chorion-gonadotrofine (hCG), zo mogelijk, te worden achtergehouden. </span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Vrouwen in de vruchtbare leeftijd dienen niet-hormonale anticonceptie te gebruiken tijdens de behandeling met gosereline tot herstel van de menstruatie na het stopzetten van de behandeling met gosereline. </span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Pati&#235;nten met hypertensie dienen zorgvuldig gecontroleerd te worden.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029806","display":"4.4 Bijzondere waarschuwingen en voorzorgen bij gebruik"}]}},{"id":"b90ab899-a745-ee11-be6f-000d3aaa0218","title":"4.5 Interacties met andere geneesmiddelen en andere vormen van interactie","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt;\">Omdat androgeendeprivatietherapie (suppressie van de testosteronproductie bij prostaatcarcinoom) het QT-interval kan verlengen, moet er een zorgvuldige afweging worden gemaakt als gosereline gelijktijdig gebruikt wordt met geneesmiddelen waarvan bekend is dat ze het QT-interval kunnen verlengen of geneesmiddelen die Torsade de pointes kunnen induceren, zoals klasse IA (bijv. kinidine, disopyramide) of klasse III (bijv. amiodaron, sotalol, dofetilide, ibutilide) anti-aritmica, methadon, moxifloxacine, antipsychotica, etc. (zie rubriek 4.4).</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\">&#160;</p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029809","display":"4.5 Interacties met andere geneesmiddelen en andere vormen van interactie"}]}},{"id":"bb0ab899-a745-ee11-be6f-000d3aaa0218","title":"4.6 Vruchtbaarheid, zwangerschap en borstvoeding","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">&#160;</div>"},"section":[{"id":"bc0ab899-a745-ee11-be6f-000d3aaa0218","title":"Zwangerschap","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zoladex dient niet te worden toegepast tijdens een zwangerschap, omdat het gebruik van LHRH-agonisten wordt geassocieerd met een theoretisch risico op een spontane abortus of op foetale afwijkingen. Bij vrouwen in de vruchtbare leeftijd dient voor instelling op de therapie eerst een eventuele zwangerschap zorgvuldig te worden uitgesloten. Tijdens de behandeling dienen niet-hormonale anticonceptiemethoden te worden toegepast totdat de menstruaties weer optreden (zie ook rubriek 4.4)</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029812","display":"Zwangerschap"}]}},{"id":"bd0ab899-a745-ee11-be6f-000d3aaa0218","title":"Borstvoeding","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zoladex is gecontra-indiceerd tijdens borstvoeding (zie rubriek 4.3) en dient niet te worden gebruikt tijdens het geven van borstvoeding.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029813","display":"Borstvoeding"}]}}],"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029811","display":"4.6 Vruchtbaarheid, zwangerschap en borstvoeding"}]}},{"id":"bf0ab899-a745-ee11-be6f-000d3aaa0218","title":"4.7 Beïnvloeding van de rijvaardigheid en het vermogen om machines te bedienen","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Er zijn geen aanwijzingen dat Zoladex de rijvaardigheid en het vermogen om machines te bedienen nadelig zou be&#239;nvloeden.</p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029815","display":"4.7 Beïnvloeding van de rijvaardigheid en het vermogen om machines te bedienen"}]}},{"id":"c00ab899-a745-ee11-be6f-000d3aaa0218","title":"4.8 Bijwerkingen","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"line-height: normal; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">De volgende frequentiecategorie&#235;n zijn gebaseerd op alle bijwerkingen uit klinisch onderzoek, post-marketingonderzoek en spontane meldingen. Bijwerkingen die het meest werden waargenomen zijn opvliegers, transpireren en reacties op de injectieplaats.</p>\n<p style=\"line-height: normal; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p>\n<p style=\"line-height: normal; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">De volgende conventie is gebruikt voor de classificatie van frequenties:</p>\n<p style=\"line-height: normal; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Zeer vaak (<span style=\"font-family: Symbol;\">&#179;</span>1/10), Vaak (<span style=\"font-family: Symbol;\">&#179;</span>1/100, &lt;1/10), Soms (<span style=\"font-family: Symbol;\">&#179;</span>1/1.000, &lt;1/100), Zelden (<span style=\"font-family: Symbol;\">&#179;</span>1/10.000, &lt;1/1.000), Zeer zelden (&lt;1/10.000), niet bekend (kan met de beschikbare gegevens niet worden bepaald).</p>\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n<table class=\"MsoNormalTable\" style=\"width: 100%; border-collapse: collapse; border: none;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<thead>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\">Orgaansysteem</p>\n</td>\n<td style=\"width: 63.8pt; border: solid windowtext 1.0pt; border-left: none; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\">Frequentie</p>\n</td>\n<td style=\"width: 163.0pt; border: solid windowtext 1.0pt; border-left: none; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\">Mannen</p>\n</td>\n<td style=\"width: 153.95pt; border: solid windowtext 1.0pt; border-left: none; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\">Vrouwen</p>\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><u>(all&#233;&#233;n Zoladex-3,6)</u></p>\n</td>\n</tr>\n</thead>\n<tbody>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\">&#160;</p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" rowspan=\"2\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Neoplasmata, benigne, maligne en niet-gespecificeerd (inclusief cysten en poliepen)</span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Zeer zelden</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Hypofysetumor</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Hypofysetumor</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Niet bekend</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Degeneratie van uterusfibro&#239;den bij vrouwen met uterusfibro&#239;den</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" rowspan=\"2\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Immuunsysteem&#173;aandoeningen</span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Soms</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Geneesmiddel&#173;overgevoeligheid</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Geneesmiddel&#173;overgevoeligheid</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Zelden</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Anafylactische reactie</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Anafylactische reactie</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Endocriene aandoeningen</span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Zeer zelden</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Hypofyseapoplexie, hypofysebloeding</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Hypofyseapoplexie, hypofysebloeding</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" rowspan=\"2\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Voedings- en stofwisselingsstoornissen</span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Verlaging van de glucosetolerantie<sup>a </sup></span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Soms</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Hypercalci&#235;mie</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" rowspan=\"3\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Psychische stoornissen</span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Zeer vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Libido-afname<sup>b</sup></span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Libido-afname<sup>b</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Stemmingswisselingen, depressie</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Stemmingswisselingen, depressie</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Zeer zelden</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Psychotische stoornis</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Psychotische stoornis</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Zenuwstelselaandoeningen</span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Paresthesi&#235;n</span></p>\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Compressie van de rugwervel</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Paresthesi&#235;n</span></p>\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Hoofdpijn</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border-top: none; border-left: solid windowtext 1.0pt; border-bottom: none; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Hart aandoeningen</span></p>\n</td>\n<td style=\"width: 63.8pt; border: none; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border: none; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Hartfalen<sup>f, </sup>myocardinfarct<sup>f</sup></span></p>\n</td>\n<td style=\"width: 153.95pt; border: none; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Onbekend</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">QT-verlenging (zie rubrieken 4.4 en 4.5)</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border-top: none; border-left: solid windowtext 1.0pt; border-bottom: solid windowtext 1.0pt; border-right: none; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 63.8pt; border: none; border-bottom: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 163.0pt; border: none; border-bottom: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" rowspan=\"2\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Bloedvataandoeningen </span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Zeer vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Opvliegers<sup>b</sup></span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Opvliegers<sup>b</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Bloeddruk abnormaal<sup>c</sup></span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Bloeddruk abnormaal<sup>c</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border-top: none; border-left: solid windowtext 1.0pt; border-bottom: none; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" rowspan=\"2\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Huid- en onderhuidaandoeningen </span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Zeer vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Hyperhidrose<sup>b</sup></span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Hyperhidrose<sup>b</sup>, acne<sup>j</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Huiduitslag<sup>d</sup></span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Huiduitslag<sup>d</sup>, alopecia<sup>g</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Niet bekend</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Alopecia<sup>h</sup></span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" rowspan=\"2\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Skeletspierstelsel- en bindweefselaandoeningen </span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Botpijn<sup>e</sup></span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Artralgie </span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Soms</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Artralgie</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Nier- en urinewegaandoeningen </span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Soms</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Ureterobstructie</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" rowspan=\"5\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Voortplantingsstelsel- en borstaandoeningen </span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Zeer vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Erectiestoornissen</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vulvovaginale droogheid</span></p>\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vergroting van de borst</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Gynaecomastie</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Soms</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Gevoelige borsten</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Zelden</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Ovariumcysten</span></p>\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Ovarium hyperstimulatie&#173;syndroom </span><span style=\"font-weight: normal;\">(zie rubriek 4.4)<sup>i</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Frequentie onbekend</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Onttrekkingsbloeding (zie rubriek 4.4)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" rowspan=\"2\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Algemene aandoeningen en toedieningsplaatsstoornissen </span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Zeer vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Reacties op de injectieplaats (zoals roodheid, pijn, zwelling, hemorragie)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Reacties op de injectieplaats (zoals roodheid, pijn, zwelling, hemorragie)</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Tumor flare, tumorpijn</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 522.55pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" colspan=\"4\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">&#160;</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside: avoid;\">\n<td style=\"width: 141.8pt; border: solid windowtext 1.0pt; border-top: none; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Onderzoeken</span></p>\n</td>\n<td style=\"width: 63.8pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Vaak</span></p>\n</td>\n<td style=\"width: 163.0pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Afname van botdichtheid (zie rubriek 4.4), gewichtstoename</span></p>\n</td>\n<td style=\"width: 153.95pt; border-top: none; border-left: none; border-bottom: solid windowtext 1.0pt; border-right: solid windowtext 1.0pt; padding: 0in 2.85pt 0in 2.85pt;\" valign=\"top\">\n<p style=\"text-align: left; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif; font-weight: bold;\"><span style=\"font-weight: normal;\">Afname van botdichtheid (zie rubriek 4.4), gewichtstoename</span></p>\n</td>\n</tr>\n</tbody>\n</table>\n<ol style=\"list-style-type: lower-alpha; margin-bottom: 0in; margin-top: 0px;\">\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\">Een afname van glucosetolerantie is aangetoond bij mannen die met LHRH-agonisten behandeld werden. Dit kan zich uiten als diabetes of verlies van glykemiecontrole bij pati&#235;nten die reeds diabetes mellitus hebben (zie rubriek 4.4). </span></li>\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\">Dit zijn farmacologische effecten die zelden het stopzetten van de therapie noodzakelijk maken. Hyperhidrose en opvliegers kunnen blijven bestaan na stoppen van het gebruik ven Zoladex. </span></li>\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\">Deze kunnen zich manifesteren in de vorm van hypotensie of hypertensie, en zijn af en toe waargenomen bij pati&#235;nten die </span><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zoladex</span><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\"> toegediend kregen. De veranderingen zijn gewoonlijk van voorbijgaande aard, verdwijnen ofwel gedurende de therapie of na het stopzetten van de therapie met </span><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zoladex</span><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\">. Deze veranderingen leidden zelden tot medisch ingrijpen inclusief het stopzetten van de therapie.</span></li>\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\">Deze zijn in het algemeen mild, en verminderen vaak zonder be&#235;indiging van de therapie.</span></li>\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\">Pati&#235;nten met prostaatkanker kunnen aanvankelijk een tijdelijke verergering van botpijn ervaren, deze kunnen symptomatisch worden behandeld.</span></li>\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\">Geobserveerd in een farmacoepidemiologische studie van LHRH-agonisten gebruikt bij de behandeling van prostaatkanker. Het risico lijkt toe te nemen indien gebruikt in combinatie met anti-androgenen.</span></li>\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\">Verlies van hoofdhaar is gerapporteerd bij vrouwen, inclusief jongere pati&#235;nten die behandeld worden voor benigne aandoeningen. Deze zijn over het algemeen mild maar kunnen soms ook ernstig zijn.</span></li>\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\">Vooral het verlies van lichaamshaar is een verwacht effect door verlaagde androgeenspiegels.</span></li>\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\">Indien gebruikt in combinatie met gonadotrofine.</span></li>\n<li style=\"margin: 0in 0in 0in 0px; font-size: 12pt; font-family: 'CG Times', serif; text-indent: 14.2px;\"><span style=\"font-size: 10.0pt; font-family: 'Times New Roman', serif;\">In de meeste gevallen werd acne binnen 1 maand na het starten van de behandeling met Zoladex gemeld.</span></li>\n</ol>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><strong><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Post-marketingervaring</span></strong></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Een klein aantal gevallen van veranderingen in de bloedtelling, leverdisfunctie, longembolie en interstiti&#235;le pneumonie zijn gerapporteerd in relatie met gosereline.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">All&#233;&#233;n voor </span></u><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zoladex</span></u><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">-3,6 (all&#233;&#233;n voor vrouwen)</span></u></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Bovendien zijn de volgende bijwerkingen gemeld bij vrouwen die behandeld werden voor goedaardige gynaecologische indicaties:</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Acn&#233;, verandering van lichaamsbeharing, droge huid, gewichtstoename, toename van serumcholesterine, vaginitis, vaginale afscheiding, nervositeit, slaapstoornis, moeheid, perifeer oedeem, myalgi&#235;n, kramp in de kuiten, misselijkheid, braken, diarree, obstipatie, buikklachten, stemveranderingen.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Pati&#235;nten met borstkanker kunnen aanvankelijk een tijdelijke verhoging van tekenen en symptomen ervaren, die symptomatisch behandeld kunnen worden.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Borstkankerpati&#235;nten met metastasen hebben zelden hypercalci&#235;mie ontwikkeld bij het instellen van de therapie<em>. Hypercalci&#235;mie moet worden uitgesloten als symptomen van hypercalci&#235;mie (zoals dorst), aanwezig zijn.</em></span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Enkele vrouwen kunnen in de menopauze terechtkomen tijdens behandeling met LHRH-analoga en bij wie de menstruatie niet terugkeert na het staken van de therapie. Dit treedt zelden op. Het is niet bekend of dit een gevolg is van behandeling met gosereline of een reflectie van hun gynaecologische toestand.</span></p></div>"},"section":[{"id":"c20ab899-a745-ee11-be6f-000d3aaa0218","title":"Melding van vermoedelijke bijwerkingen","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-size: 12.0pt; font-family: 'CG Times', serif;\">Het is belangrijk om na toelating van het geneesmiddel vermoedelijke bijwerkingen te melden. Op deze wijze kan de verhouding tussen voordelen en risico&#8217;s van het geneesmiddel voortdurend worden gevolgd. Beroepsbeoefenaren in de gezondheidszorg wordt verzocht alle vermoedelijke bijwerkingen te melden via het Nederlands Bijwerkingen Centrum Lareb, website <span style=\"color: #0563c1;\"><span style=\"text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;\"><u><a href=\"https://www.lareb.nl\">www.lareb.nl</a></u></span></span>.</span></p>\n<p>&#160;</p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029818","display":"Melding van vermoedelijke bijwerkingen"}]}}],"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029816","display":"4.8 Bijwerkingen"}]}},{"id":"c30ab899-a745-ee11-be6f-000d3aaa0218","title":"4.9 Overdosering","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Er is niet veel ervaring met humane overdosering. In gevallen waarbij gosereline is toegediend v&#243;&#243;r de geplande toedieningstijd, of als een hogere dosis gosereline is toegediend dan aanvankelijk was bedoeld, zijn geen klinisch significante ongewenste effecten waargenomen. Dierexperimenteel onderzoek doet vermoeden dat bij hogere doseringen van Zoladex geen ander effect zal optreden dan de beoogde therapeutische effecten op de concentraties geslachtshormonen en op de geslachtsorganen. Gevallen van overdosering dienen symptomatisch te worden behandeld.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029819","display":"4.9 Overdosering"}]}}],"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029798","display":"4. KLINISCHE GEGEVENS"}]}},{"id":"c50ab899-a745-ee11-be6f-000d3aaa0218","title":"5. FARMACOLOGISCHE EIGENSCHAPPEN","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">&#160;</div>"},"section":[{"id":"c60ab899-a745-ee11-be6f-000d3aaa0218","title":"5.1 Farmacodynamische eigenschappen","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">ATC-code: L02AE03</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Gosereline is een synthetisch analogon van het natuurlijke in de hypothalamus geproduceerde LHRH. Het gosereline heeft een stimulerende werking op de LH- en FSH-vrijgifte door de hypofyse. Aanvankelijk treedt een stimulering op van de hypofyse-gonade as, hetgeen zich manifesteert in een tijdelijke verhoging van de LH‑, FSH-, oestradiol- en testosteron-secretie. Bij voortgezet gebruik, echter, treedt suppressie op, mogelijk veroorzaakt door uitputting en ongevoelig worden van de gonadotrope hypofysecellen.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><strong><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></strong></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Door het uitblijven van de LH-stimulatie vermindert de serumtestosteronconcentratie bij mannen en de serumoestradiolconcentratie bij vrouwen, terwijl de LH-receptoren in de gonaden geleidelijk in aantal afnemen. Het gevolg hiervan is dat na circa 21 dagen de testosteronproductie daalt tot het niveau dat normaal optreedt bij castratie. Bij vrouwen leidt de chronische toediening na circa 21 dagen tot een serum oestradiol concentratie zoals bij post-menopauzale vrouwen. De daling van de hormoonconcentraties blijft gehandhaafd na herhaling van toediening </span><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">van Zoladex‑10,8 iedere 3 maanden bij mannen respectievelijk van Zoladex‑3,6 iedere 4&#160;weken bij mannen en vrouwen. Indien onder buitengewone omstandigheden herhaalde toediening van Zoladex-10,8 niet na 3 maanden plaatsvindt, wijzen gegevens er op dat bij de meerderheid van de pati&#235;nten de testosteronconcentratie tot 16 weken op castratieniveau gehandhaafd blijft.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif; line-height: 1;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Bij mannen leidt de hormoonsuppressie tot regressie van het prostaatcarcinoom. Bij vrouwen leidt de hormoonsuppressie tot het slinken van het endometrium. Bij vrouwen met endometriose of fibromyomen leidt hormoonsuppressie tot minder klachten zoals pijn in de onderbuik, dyspareunie en dysmenorroe; bij vrouwen met endometriose tot vermindering van de endometriosehaarden en bij vrouwen met fibromyomen tot afname van de tumorgrootte. Dit zal gepaard gaan met het uitblijven van de menstruatie bij de meerderheid van de vrouwelijke pati&#235;nten. Het staken van de therapie resulteert in een herstel van de normale hypofyse-gonade-as-activiteit.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif; line-height: 1;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">In het begin van de therapie met Zoladex treden bij sommige vrouwen bloedingen op die verschillend van duur en intensiteit zijn. Dit soort bloedingen zijn waarschijnlijk oestrogeen-onttrekkingsbloedingen die geacht worden spontaan te stoppen. </span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif; line-height: 1;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Gedurende de behandeling met een LHRH-analoog kunnen pati&#235;nten in de overgang raken. Zelden keert na het staken van de Zoladex behandeling de menstruatie niet terug.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029822","display":"5.1 Farmacodynamische eigenschappen"}]}},{"id":"cb0ab899-a745-ee11-be6f-000d3aaa0218","title":"5.2 Farmacokinetische eigenschappen","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Toediening van Zoladex‑10,8 iedere 3 maanden bij mannen respectievelijk Zoladex‑3,6 iedere 4 weken bij mannen en vrouwen, zorgt voor voldoende onderhoud van de therapie met gosereline zonder klinisch relevante cumulatie. Piekserumconcentraties worden binnen circa 2 weken na toediening bereikt. Gosereline wordt in geringe mate gebonden aan eiwitten en de serum eliminatiehalfwaardetijd bedraagt twee tot vier uur bij pati&#235;nten met normale nierfunctie.</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\">&#160;</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif; line-height: 1;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Bij pati&#235;nten met gestoorde nierfunctie is de eliminatiehalfwaardetijd verlengd. Bij toediening van gosereline volgens voorschrift leidt deze verlenging van de halfwaardetijd niet tot klinisch relevante cumulatie. Dosisaanpassing is dan ook niet nodig bij pati&#235;nten met gestoorde nierfunctie.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\">&#160;</p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Er is geen significant verschil in de farmacokinetiek bij pati&#235;nten met een gestoorde leverfunctie.</span></p>\n<p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">&#160;</p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029827","display":"5.2 Farmacokinetische eigenschappen"}]}},{"id":"d20ab899-a745-ee11-be6f-000d3aaa0218","title":"5.3 Gegevens uit het preklinisch veiligheidsonderzoek","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Na langdurige therapie met Zoladex is bij mannelijke ratten een verhoogde incidentie van goedaardige hypofysetumoren waargenomen. Deze waarneming is vergelijkbaar met datgene wat werd waargenomen na castratie van mannelijke ratten. De humane relevantie hiervan is niet vastgesteld.</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Na langdurige therapie met Zoladex, waarbij veelvouden van hogere doses werden gebruikt dan noodzakelijk voor de humane therapie, zijn bij muizen histologische veranderingen waargenomen in het maagdarmkanaal, welke zich manifesteerden als hyperplasie van eilandcellen in de pancreas en goedaardige proliferatie van het pylorisgebied van de maag. Deze zijn tevens opgemerkt als spontane stoornissen bij deze species. De klinische relevantie van deze bevindingen is niet bekend.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029834","display":"5.3 Gegevens uit het preklinisch veiligheidsonderzoek"}]}}],"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029821","display":"5. FARMACOLOGISCHE EIGENSCHAPPEN"}]}},{"id":"d40ab899-a745-ee11-be6f-000d3aaa0218","title":"6. FARMACEUTISCHE GEGEVENS","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">&#160;</div>"},"section":[{"id":"d60ab899-a745-ee11-be6f-000d3aaa0218","title":"6.1 Lijst van hulpstoffen","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Lactide/glycolide copolymeren.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029837","display":"6.1 Lijst van hulpstoffen"}]}},{"id":"e20ab899-a745-ee11-be6f-000d3aaa0218","title":"6.2 Gevallen van onverenigbaarheid","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Niet van toepassing</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029838","display":"6.2 Gevallen van onverenigbaarheid"}]}},{"id":"e30ab899-a745-ee11-be6f-000d3aaa0218","title":"6.3 Houdbaarheid","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">3&#160;jaar.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029839","display":"6.3 Houdbaarheid"}]}},{"id":"e40ab899-a745-ee11-be6f-000d3aaa0218","title":"6.4 Speciale voorzorgsmaatregelen bij bewaren","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Bewaren beneden 25&#176;C.</p>\n<p style=\"margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">Bewaren in de oorspronkelijke verpakking.</p>\n<p style=\"margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\"><span style=\"font-size: 12.0pt; font-family: 'CG Times', serif;\">De aluminium enveloppe zorgvuldig gesloten houden.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029840","display":"6.4 Speciale voorzorgsmaatregelen bij bewaren"}]}},{"id":"e90ab899-a745-ee11-be6f-000d3aaa0218","title":"6.5 Aard en inhoud van de verpakking","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">De voorgevulde injectiespuit (SafeSystem) met steriel implantatiestaafje is verpakt in een gesloten aluminium enveloppe met desiccans. De aluminium enveloppe is vervolgens verpakt in een omdoos.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029841","display":"6.5 Aard en inhoud van de verpakking"}]}},{"id":"ea0ab899-a745-ee11-be6f-000d3aaa0218","title":"6.6 Speciale voorzorgsmaatregelen voor het verwijderen en andere instructies","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Toedienen volgens voorschrift van de voorschrijvende arts.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zie voor meer informatie rubriek 4.2.</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Alleen gebruiken indien de verpakking (aluminium enveloppe) onbeschadigd is. Na openen van de aluminium enveloppe direct gebruiken.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029842","display":"6.6 Speciale voorzorgsmaatregelen voor het verwijderen en andere instructies"}]}}],"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029836","display":"6. FARMACEUTISCHE GEGEVENS"}]}},{"id":"ec0ab899-a745-ee11-be6f-000d3aaa0218","title":"7. HOUDER VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Houder van de vergunning:</span></u></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">AstraZeneca BV</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Prinses Beatrixlaan 582</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">2595 MB Den Haag</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029844","display":"7. HOUDER VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN"}]}},{"id":"ed0ab899-a745-ee11-be6f-000d3aaa0218","title":"8. NUMMER(S) VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"text-align: left; line-height: normal; break-after: auto; margin: 0in; font-size: 11pt; font-family: 'Times New Roman', serif;\">In het register ingeschreven onder:</p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">RVG 12277 (Zoladex‑3,6)</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">RVG 18562 (Zoladex‑10,8)</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029845","display":"8. NUMMER(S) VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN"}]}},{"id":"ee0ab899-a745-ee11-be6f-000d3aaa0218","title":"9. DATUM VAN EERSTE VERLENING VAN DE VERGUNNING/VERLENGING VAN DE VERGUNNING","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zoladex‑3,6</span></u></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Datum van eerste verlening van de vergunning:&#160;&#160; 03-10-1988</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Datum van laatste verlenging:&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;03-10-2013</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">&#160;</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><u><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Zoladex‑10,8</span></u></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Datum van eerste verlening van de vergunning:&#160;&#160; 20-10-1995</span></p>\n<p style=\"margin: 0in; font-size: 12pt; font-family: 'CG Times', serif;\"><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Datum van laatste verlenging:&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;20-10-2015</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029846","display":"9. DATUM VAN EERSTE VERLENING VAN DE VERGUNNING/VERLENGING VAN DE VERGUNNING"}]}},{"id":"ef0ab899-a745-ee11-be6f-000d3aaa0218","title":"10. DATUM VAN HERZIENING VAN DE TEKST","text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><span style=\"font-size: 11.0pt; font-family: 'Times New Roman', serif;\">Laatste gedeeltelijke wijziging betreft de opmaak: 2 augustus 2019.</span></p></div>"},"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029847","display":"10. DATUM VAN HERZIENING VAN DE TEKST"}]}}],"code":{"coding":[{"system":"https://spor.ema.europa.eu/v1/lists/200000029659/terms/","code":"200000029791","display":"SAMENVATTING VAN DE PRODUCTKENMERKEN"}]}}]}}]}